Zika vaccine produces promising results in human trial
by Press Release from Outbreak News Today on (#263YB)
Inovio Pharmaceuticals, Inc. today announced its DNA-based Zika vaccine (GLS-5700) generated robust antigen-specific antibody responses in a first-in-man, multi-center phase I trial. In initial testing, Zika-naive subjects in both low dose and high dose vaccine groups demonstrated Zika antigen-specific antibody responses after one or two vaccinations. In addition, the vaccine was well tolerated and no ["]
The post Zika vaccine produces promising results in human trial appeared first on Outbreak News Today.